drugset / Trial / NCT05548088
LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML
Phase 1
Completed
11 enrolled
Peking University People's Hospital
Bristar Immunotech Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an exploratory study to evaluate the safety, tolerability, and efficacy of LILRB4 STAR-T cells in relapsed and refractory acute myeloid leukemia/Chronic Granulocytic-Mononocytic Leukemia subjects.
Timeline
- Start
- 2023-05-25
- Primary completion
- 2024-08-03
- Completion
- 2024-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LILRB4 STAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T cells | Cell therapy | 3e+06 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T cells | Cell therapy | 6e+06 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T cells | Cell therapy | 1e+07 cells/kg | Intravenous |